Real-world evidence for medical affairs: who can actually use it?

Real-World Evidence (RWE) is increasingly critical for pharmaceutical regulatory, payer, and clinical decisions, but companies struggle to rapidly generate and communicate insights from their data assets.

• •RWE is analyzed health information from routine patient care (EHRs, claims), versus RWD which is raw data
• •Four commercial uses: regulatory label expansion, payer formulary placement, HCP scientific exchange, and internal pipeline decisions
• •Most companies have RWE data assets but lack operational fluency to quickly generate competitive insights
• •Databricks Genie enables natural language queries on RWE data, completing analyses in seconds that would take data scientists days

This summary was automatically generated by AI based on the original article and may not be fully accurate.